Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Valoctocogene Roxaparvovec
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Medicover
Deal Size : Undisclosed
Deal Type : Partnership
Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union
Details : Under the partnership, ARUP Laboratories developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A eligible for treatment with Roctavian (valoctocogene roxaparvovec-rvox), a new gene therapy...
Product Name : Roctavian
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 12, 2023
Lead Product(s) : Valoctocogene Roxaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Medicover
Deal Size : Undisclosed
Deal Type : Partnership